Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Next Previous
X
Search
Trial Profile

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic

    • Most Recent Events

    • 27 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 30 May 2023 Planned primary completion date changed from 30 Jun 2021 to 31 Dec 2023.
    • 07 Jun 2022 Results assessing whether GP5 predicts early aromatase inhibitor discontinuation in the racially diverse, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top